Poor water solubility is one of the most significant barrier limiting drug development. Indeed, more than 40% of compounds identified through combinatorial screening programs display poor aqueous solubility, which is associated with poor bioavailability, suboptimal dosing, etc. Adjuvatis uses a safe-by-design technology that allows formulation of APIs with little or no solubility. Adjuvatis develops biocompatible[...]